Ezgi B Ulas

6PUBLICATIONS
24CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 22, 2026
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

|May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

|Nov 28, 2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC.

Ezgi B Ulas, Sofie J I Koomen, Anne Vrijmoet

|Aug 13, 2025
The role of perioperative chemoimmunotherapy in resectable non-small cell lung cancer: insights from the NADIM trial.

Amira de Koning, Ilias Houda, Ezgi B Ulas

|Sep 30, 2024
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.

Idris Bahce, Chris Dickhoff, Famke L Schneiders

|Feb 01, 2024
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.

Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman

Pageof 1

Frequent Collaborators

5 joint publications

Idris Bahce

3 joint publications

Febe van Maldegem

3 joint publications

Marieke F Fransen

3 joint publications

Suresh Senan